Brokerages forecast that Heska Co. (NASDAQ:HSKA) will post $0.40 earnings per share for the current quarter, according to Zacks. Two analysts have made estimates for Heska’s earnings, with the lowest EPS estimate coming in at $0.37 and the highest estimate coming in at $0.43. Heska reported earnings of $0.61 per share in the same quarter last year, which would indicate a negative year over year growth rate of 34.4%. The company is expected to issue its next earnings results on Tuesday, May 1st.
According to Zacks, analysts expect that Heska will report full-year earnings of $1.95 per share for the current year, with EPS estimates ranging from $1.90 to $2.00. For the next financial year, analysts expect that the firm will post earnings of $2.17 per share, with EPS estimates ranging from $2.13 to $2.20. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research analysts that that provide coverage for Heska.
Heska (NASDAQ:HSKA) last announced its earnings results on Wednesday, February 28th. The medical research company reported $0.63 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.56 by $0.07. The firm had revenue of $36.04 million for the quarter, compared to analysts’ expectations of $40.56 million. Heska had a return on equity of 16.23% and a net margin of 7.53%. The firm’s quarterly revenue was down 8.8% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.46 earnings per share.
Hedge funds and other institutional investors have recently bought and sold shares of the business. TimesSquare Capital Management LLC purchased a new position in Heska during the 4th quarter worth approximately $23,831,000. Park West Asset Management LLC grew its position in Heska by 293.3% during the 4th quarter. Park West Asset Management LLC now owns 347,646 shares of the medical research company’s stock worth $27,885,000 after purchasing an additional 259,256 shares in the last quarter. Redmile Group LLC purchased a new position in Heska during the 4th quarter worth approximately $15,753,000. Atlantic Trust Group LLC purchased a new position in Heska during the 3rd quarter worth approximately $16,059,000. Finally, Neuberger Berman Group LLC grew its position in Heska by 34.2% during the 3rd quarter. Neuberger Berman Group LLC now owns 603,469 shares of the medical research company’s stock worth $53,160,000 after purchasing an additional 153,895 shares in the last quarter. 85.21% of the stock is currently owned by institutional investors.
Shares of NASDAQ HSKA traded down $0.42 during trading on Friday, hitting $74.50. The company had a trading volume of 72,705 shares, compared to its average volume of 92,128. The stock has a market capitalization of $553.35, a P/E ratio of 35.99, a P/E/G ratio of 2.07 and a beta of 0.65. Heska has a 52 week low of $56.59 and a 52 week high of $115.00.
Heska Company Profile
Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal Health segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; HT5 and HEMATRUE veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; COAG veterinary analyzers; Element i immunodiagnostic analyzers; and IV infusion pumps.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.